ROTTERDAM, Netherlands and SAN DIEGO, April 20, 2023 /PRNewswire/ -- SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, today announced its first non-academic strategic partnership with NeraCare GmbH from Frankfurt, Germany to co-develop a test to help life science companies bring lifesaving melanoma therapies to market.
ROTTERDAM, Netherlands and SAN DIEGO, March 24, 2022 /PRNewswire/ -- Today, SkylineDx announced that their Merlin Test for melanoma patients was independently validated in a Swedish (European) cohort, where it could reduce approximately a third of the surgeries in the clinically most relevant patient group (patients with pT1-2 melanomas) [2]. The Merlin Test identifies melanoma patients that can safely forgo a sentinel lymph node biopsy (SLNB) surgery, a procedure used to determine metastatic spread of the cancer for staging purposes. In approximately 80% of patients the biopsy comes back negative for metastasis and does not further impact the patient pathway. The Merlin Test provides a more personalized insight on the metastatic propensity of the tumor. The patient with a low-risk tumor could avoid surgery [3]. Results have been published in a peer-reviewed and scientific journal, the European Journal of Surgical Oncology [2].
ROTTERDAM, Netherlands and SAN DIEGO and GHENT, Belgium, Dec. 22, 2021 /PRNewswire/ -- Today, SkylineDx announced a 3-year strategic partnership with life sciences institute VIB for the evaluation and initiation of collaborative projects focused on molecular diagnostics. Under the agreement, SkylineDx and VIB will jointly evaluate opportunities regarding novel molecular diagnostics, combining VIB's expertise in state-of-the-art single-cell analysis and biomarker discovery applied to molecular pathology and precision diagnostics with SkylineDx' strategic expertise, global network of renowned clinical centers and physicians, and know-how in the development, market access and early commercialization of in vitro diagnostics.
ROTTERDAM, Netherlands and SAN DIEGO and GHENT, Belgium, Dec. 22, 2021 /PRNewswire/ -- Today, SkylineDx announced a 3-year strategic partnership with life sciences institute VIB for the evaluation and initiation of collaborative projects focused on molecular diagnostics. Under the agreement, SkylineDx and VIB will jointly evaluate opportunities regarding novel molecular diagnostics, combining VIB's expertise in state-of-the-art single-cell analysis and biomarker discovery applied to molecular pathology and precision diagnostics with SkylineDx' strategic expertise, global network of renowned clinical centers and physicians, and know-how in the development, market access and early commercialization of in vitro diagnostics.
Today, SkylineDx announced that the first hospitals will start including melanoma patients in a large prospective clinical study in the United States, to validate the Merlin Assay. A total of 10 hospitals are collaborating in this trial, including Moffitt Cancer Center, Mayo Clinic and University of Louisville School of Medicine led by the respective principal investigators [2]. In the coming two years, over 2,000 patients with invasive malignant melanoma (skin cancer) indicated for a sentinel lymph node surgery, will be enrolled and followed during 5 years [2].